Renal Cell Carcinoma

Rana R. McKay, MD, discussed the implications of the KEYNOTE-564 study along with the future of adjuvant immunotherapy in RCC, in an interview with Targeted Oncology

In an interview with Targeted Oncology, Nicholas J. Vogelzang, MD, discussed how the treatment landscape has changed for renal cell carcinoma and the continuing promise of lenvatinib.

Proactive management of treatment-emergent adverse events, including treatment interruption, may be crucial for patients with renal cell carcinoma receiving lenvatinib in combination with pembrolizumab, according to the CLEAR study investigators.

Despite advanced in the field of renal cell carcinoma, most patients still die of the disease and more options and new targets are needed, says Moshe C. Ornstein, MD, MA.

During a live virtual event, Sandy Srinivas, MD, discussed results from the CLEAR trial of lenvatinib and pembrolizumab in renal cell carcinoma and the participants' experiences with the regimen including dose reductions needed by their patients across multiple cancer types.

Based on the case of a man with metastatic renal cell carcinoma, Brian Rini, MD, and peers discussed later-line immunotherapy and tyrosine kinase inhibitor combination therapies.

In an interview with Targeted Oncology, Eric Jonasch, MD, discussed the impact belzutifan has had on the VHL-assocaited renal cell carcinoma space, along with unmet clinical needs the agent is addressing.

In an interview with Targeted Oncology, Viraj Master, MD, PhD, FACS , discussed how adjuvant pembrolizumab may impact the treatment landscape of renal cell carcinoma.

In a post-hoc analysis of the CheckMate 9ER trial, researchers found that, along with additional efficacy benefits, the combination of nivolumab plus cabozantinib had manageable adverse events.

The FDA has approved adjuvant pembrolizumab for the treatment of renal cell carcinoma with an intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.

A significant reduction in the number of patients experiencing grade 3 or 4 toxicity was observed with modified dosing as ipilimumab combine with nivolumab in patients with advanced renal cell carcinoma.

The novel combination of belzutifan and lenvatinib will be tested against cabozantinib in a phase 3 clinical trial of patients with advanced renal cell carcinoma.

Compared with systemic therapy administered after cytoreductive nephrectomy, active surveillance was an option for some patients with metastatic renal cell carcinoma.

The combination of lenvatinib and pembrolizumab is the current standard of care for ccRCC, however, most patients still experience disease progression. The addition of a third agent may lead to improvement in outcomes.

Compared with sunitinib, the combination of nivolumab an ipilimumab produced better long-term responses, with overall survival approaching 5 years.

New findings suggest that understanding subtypes of non-clear cell renal cell carcinoma is important for personalizing treatment.

James Brugarolas, MD, PhD, discusses updated survival data in patients with metastatic renal cell carcinoma.

The frontline combination of lenvatinib and pembrolizumab is under investigation as a treatment option for patients with non-clear cell renal cell carcinoma in the recently launched phase 2 KEYNOTE-B61 trial.

While immunotherapy has high and durable response rates, most patients die of the disease.

Savolitinib in combination with durvalumab has been dosed to the first patient with MET-driven advanced papillary renal cell carcinoma in a phase 3 study.